Highlights
Zanidatamab, a bispecific antibody targeting HER2, combined with chemotherapy demonstrated a high objective response rate (76.2%) and durable clinical benefit in treatment-naïve patients with HER2-positive advanced gastro-oesophageal adenocarcinoma. The median progression-free survival reached 12.5 months, with median overall survival extending to 36.5 months. The combination therapy had a manageable safety profile, with diarrhoea and hypokalaemia as the most common grade 3-4 adverse events, and no treatment-related deaths reported.
